This is Archived Content. This content is available for historical purposes only. It may not reflect the current state of science or language from the National Institute on Drug Abuse (NIDA). View current testimonies on nida.nih.gov.
The twin addiction and overdose crises have collided with the COVID-19 pandemic, each exacerbating the deleterious effects of the other
|
Chairwoman Eshoo, Ranking Member Burgess, and members of the Subcommittee, thank you for inviting the National Institute on Drug Abuse (NIDA), a component of the National Institutes of Health (NIH)...
|
Watch the Senate Caucus on International Narcotics Control hearing Chairman Cornyn, Co-Chairwoman Feinstein and members of the Caucus on International Narcotics Control, we appreciate the opportunity to share the content...
|
Testimony by Dr. Nora Volkow, NIDA Director and others to the House Committee on Energy and Commerce
|
Testimony by Dr. Francis Collins, NIH Director and others before the Senate Committee on Health, Education, Labor & Pensions
|
Testimony by Wilson M. Compton, M.D., Deputy Director, National Institute on Drug Abuse before the House Committee on Energy and Commerce, Subcommittee on Oversight and Investigations
|
Testimony by Nora D. Volkow, M.D., Director, National Institute on Drug Abuse, before the House Subcommittee on Labor-HHS-Education Appropriations
|
Testimony by Susan R.B. Weiss, Ph.D. - Director, Division of Extramural Research, National Institute on Drug Abuse, before the Senate Judiciary Committee, Subcommittee on Crime and Terrorism
|
Testimony by Nora D. Volkow, M.D., Director, National Institute on Drug Abuse, before the Senate Judiciary Committee
|
Testimony by Nora D. Volkow, M.D., Director, National Institute on Drug Abuse, before the House Subcommittee on Labor-HHS-Education Appropriations
|
Testimony by Nora D. Volkow, Director, National Institute on Drug Abuse, before the Senate Caucus on International Narcotics Control
|
Testimony by Nora D. Volkow, Director, National Institute on Drug Abuse, before the House Committee on Energy and Commerce, Subcommittee on Oversight and Investigations
|
Mr. Chairman and Members of the Committee: I am pleased to present the Fiscal Year (FY) 2015 President’s Budget Request for the National Institute on Drug Abuse (NIDA). The FY...
|
Mr. Chairman and Members of the Subcommittee. Thank you for inviting the National Institute on Drug Abuse (NIDA), a component of the National Institutes of Health (NIH), to participate in...
|
Senate Caucus on International Narcotics Control hearing America’s Addiction to Opioids: Heroin and Prescription Drug Abuse (United States Senate Caucus on International Narcotics Control) Good Morning, Madam Chair and members...
|
Good Morning, Mr. Chairman and Members of the Subcommittee. Thank you for inviting the National Institute on Drug Abuse (NIDA), a component of the National Institutes of Health (NIH), to...
|
Mr. Chairman and Members of the Subcommittee: Thank you for inviting the National Institute on Drug Abuse, a component of the National Institutes of Health (NIH), to comment on the...
|
Senate Caucus on International Narcotics Control to Hold Hearing on Dangerous Synthetic Drugs (United States Senate Caucus on International Narcotics Control) Introduction Madame Chairwoman and Members of the Caucus: Thank...
|
Introduction Mr. Chairman and Members of the Committee: I am pleased to present the President’s budget request for the National Institute on Drug Abuse (NIDA) of the National Institutes of...
|
Introduction Mr. Chairman and Members of the Committee: I am pleased to present the President's Fiscal year 2012 Budget Request for the National Institute on Drug Abuse (NIDA). The FY...
|
Thank you for inviting the National Institute on Drug Abuse (NIDA), a component of the National Institutes of Health (NIH), an agency of the Department of Health and Human Services...
|
Mr. Chairman and Members of the Subcommittee, as the Director of the National Institute on Drug Abuse (NIDA), part of the National Institutes of Health, an agency of the Department...
|
Introduction Drug abuse and addiction are a major burden to society, with economic costs alone estimated to exceed $600 billion annually in the United States (ONDCP 2004; Rehm et al...
|
Statement for the Record Mr. Chairman and Members of the Committee: I am pleased to present the President's Fiscal Year 2010 Budget request for the National Institute on Drug Abuse...
|
Statement for the Record Thank you, Mr. Chairman and members of the Subcommittee, for the opportunity to contribute to this important discussion. The National Institute on Drug Abuse (NIDA), a...
|
Mr. Chairman, Members of the Subcommittee, and Members of the Caucus: Thank you for inviting the National Institute on Drug Abuse (NIDA), a component of the National Institutes of Health...
|
Statement for the Record Mr. Chairman and Members of the Committee: I am pleased to present the President's Budget for the National Institute on Drug Abuse (NIDA) of the National...
|
Thank you, Mr. Chairman and members of the Subcommittee, for the opportunity to contribute to this important discussion. I am Dr. Nora Volkow, Director of the National Institute on Drug...
|
Statement for the Record Mr. Chairman and Members of the Subcommittee: I am pleased to present the Fiscal Year (FY) 2008 President's budget request for the National Institute on Drug...
|
Thank you for allowing science to play a central role in this discussion. I am Dr. Nora Volkow, Director of the National Institute on Drug Abuse (NIDA), a component of...
|
Statement for the Record Mr. Chairman and Members of the Subcommittee: Thank you for inviting the National Institute on Drug Abuse (NIDA), a component of the National Institutes of Health...
|
Statement for the Record Mr. Chairman and Members of the Committee: Thank you for inviting the National Institute on Drug Abuse (NIDA), a component of the National Institutes of Health...
|
Statement for the Record Mr. Chairman and Members of the Subcommittee: I am pleased to present the Fiscal Year (FY) 2007 President's budget request for the National Institute on Drug...
|
Statement for the Record Mr. Chairman and Members of the Committee: Thank you for inviting the National Institute on Drug Abuse (NIDA), a component of the National Institutes of Health...
|
Download this report (PDF, 304KB) Introduction In compliance with Section 3633 of the Children's Health Act of 2000, Public Law 106-310, as amended by section 2502 of the 21st Century...
|
Statement for the Record Mr. Chairman and Members of the Committee: I am pleased to be here to present the President's fiscal year (FY) 2006 budget request for the National...
|
Statement for the Record Mr. Chairman and Members of the Committee: Thank you for inviting the National Institute on Drug Abuse (NIDA), a component of the National Institutes of Health...
|
Statement for the Record Mr. Chairman and Members of the Committee: I am pleased to present the Fiscal Year (FY) 2006 President's budget request for the National Institute on Drug...
|
Statement for the Record Mr. Chairman and members of the Committee: Thank you for inviting the National Institute on Drug Abuse (NIDA), a component of the National Institutes of Health...
|
Statement for the Record Mr. Chairman and Members of the Committee, I am pleased to be here to present the President's fiscal year (FY) 2005 budget request for the National...
|
Statement for the Record Chairman Souder and Members of the Subcommittee, thank you for inviting the National Institute on Drug Abuse (NIDA), a component of the National Institutes of Health...
|
Statement for the Record Mr. Chairman and Members of the Committee: I am pleased to present the President's budget request for the National Institute on Drug Abuse. The fiscal year...
|
Statement for the Record Mr. Chairman and Members of the Subcommittee, thank you for inviting the National Institute on Drug Abuse (NIDA) to participate in this important hearing. I am...
|
Statement for the Record Mr. Chairman and Members of the Committee: I am pleased to present the President's budget request for the National Institute on Drug Abuse. The fiscal year...
|
Statement for the Record Mr. Chairman and Members of the Subcommittee, thank you for the opportunity to present scientific findings about Ecstasy or MDMA. I am Dr. Glen Hanson, the...
|
Statement for the Record Mr. Chairman and members of the Subcommittee, thank you for inviting the National Institute on Drug Abuse (NIDA) to participate in this important hearing, which will...
|
Statement for the Record Mr. Chairman and Members of the Committee: I am pleased to present the President's budget request for the National Institute on Drug Abuse for FY 2003...
|
Statement for the Record Mr. Chairman and Members of the Committee, I am pleased to submit the following statement for the record discussing what we have come to learn about...
|
Statement for the Record Mr. Chairman and distinguished members of the Caucus, thank you for inviting the National Institute on Drug Abuse (NIDA) to participate in this important and timely...
|
Statement for the Record Mr. Chairman and Members of the Subcommittee, I am Susan David, Deputy Chief of the Prevention Research Branch at the National Institute on Drug Abuse (NIDA)...
|
Statement for the Record Mr. Chairman, and Members of the Committee, thank you for inviting me to participate in this important and timely hearing on MDMA. I am pleased with...
|
Summary Statement Many substances can be very effective medications when used properly, but highly addictive, dangerous, substances when misused. Morphine exemplifies this point. Morphine is a powerfully addictive drug. However...
|
Mr. Chairman, and Members of the Committee: Statement for the Record I am pleased to present the President's budget request for the National Institute on Drug Abuse, a sum of...
|
Mr. Chairman, and Members of the Committee, it is a great pleasure to be here today to share with you what we have been learning from science about the nature...
|
Statement for the Record Mr. Chairman and distinguished members of the Caucus, thank you for allowing the National Institute on Drug Abuse (NIDA) to submit a formal statement for the...
|
Statement for the Record Mr. Chairman and Members of the Subcommittee, thank you for inviting me to participate in this hearing. I am pleased to have this opportunity to tell...
|
Statement for the Record Mr. Chairman and Members of the Committee: I am pleased to present the President's non-AIDS budget request for the National Institute on Drug Abuse (NIDA) for...
|
Statement for the Record Thank you for inviting me to participate in this important hearing. I am Dr. Alan I. Leshner, the Director of the National Institute on Drug Abuse...
|
Statement for the Record There is a tremendous need to develop new and effective medications for drug addiction and to increase access to treatment. This is articulated by a number...
|
Statement for the Record Thank you for inviting me to participate in this hearing. What I would like to do this morning is illustrate through the use of some recent...
|
Statement for the Record Mr. Chairman and Members of the Committee: I am Dr. Timothy P. Condon, Associate Director of the National Institute on Drug Abuse (NIDA), one of the...
|
Statement for the Record Mr. Chairman and Members of the Committee: I am pleased to be here with my distinguished colleagues to discuss the role of the National Institute on...
|
Statement for the Record Mr. Chairman and Members of the Committee: I am pleased to be part of this distinguished panel to share with you what science has come to...
|
Statement for the Record Mr. Chairman and Members of the Subcommittee, I am Dr. Stephen Zukin, Director of the Division of Clinical and Services Research at the National Institute on...
|
Statement of the Director Mr. Chairman and Members of the Committee: I am pleased to present the President's budget request for the National Institute on Drug Abuse for Fiscal Year...
|
Statement for the Record Mr. Chairman and Members of the Committee: I am Dr. James Cooper, Associate Director for Medical Affairs, Division of Clinical and Services Research at the National...
|
The President in his FY 1999 budget has proposed that the National Institute on Drug Abuse receive $395.1 million, an increase of $35.3 million over the comparable 1998 appropriation. Including the estimated allocation for AIDS, total support provided for NIDA is $576.3 million an increase of $49.1 million over the FY 1998 appropriation. Funds for NIDA efforts in AIDS research are included within the Office of AIDS Research budget request.
|
Statement of the Director Mr. Chairman and Members of the Committee, I am pleased to be here with my distinguished colleagues to discuss current research findings and future research directions...
|
Statement for the Record Mr. Chairman and Members of the Subcommittee, I am pleased to be here with my distinguished colleagues to discuss current research findings and future research directions...
|
Statement for the Record Mr. Chairman and Members of the Subcommittee, I am pleased to share some very exciting scientific findings with you today and to tell you about our...
|